Clinical Trials on PPP3CA

Total 30 results

Novartis Pharmaceuticals

Available

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

PIK3CA-related Overgrowth Spectrum (PROS)

United States, Canada, Spain, Switzerland, France, United Kingdom, Germany, Italy, China, Hong Kong, Netherlands, Norway
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (EPIK-P3)

PIK3CA-related Overgrowth Spectrum (PROS)

Spain, France, Ireland, United States
Novartis Pharmaceuticals

Completed

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib (EPIK-P1)

PIK3CA-Related Overgrowth Spectrum (PROS)

Spain, France, Australia, United States, Ireland
Centre Hospitalier Universitaire Dijon

Terminated

Trial of Taselisib in Overgrowth (TOTEM)

PIK3CA-Related Overgrowth

France
Shanghai Jiatan Pharmatech Co., Ltd

Completed

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

PIK3CA Mutation-Related Tumors

China
Novartis Pharmaceuticals

Recruiting

Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

PIK3CA-related Overgrowth Spectrum

United States
National Human Genome Research Institute (NHGRI)

Completed

Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Genetics | Growth Disorder | PIK3CA-Related Overgrowth Spectrum (PROS)

United States
Faeth Therapeutics

Active, not recruiting

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Advanced Solid Tumor | PIK3CA Mutation | PTEN Loss of Function Mutation

United States
Novartis Pharmaceuticals
NantCell, Inc.

Terminated

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

PIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid Tumors

Spain, Belgium, United States, Canada
Centre Hospitalier Universitaire Dijon

Completed

Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA (PROMISE)

Segmental Overgrowth Disorders Due to PIK3CA

France
Pamela Munster
Novartis

Withdrawn

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Solid Tumors, Adult | HPV-Related Squamous Cell Carcinoma | Human Papillomavirus-Related Carcinoma | PIK3CA Mutation-Related Tumors | PIK3CA Mutation | Human Papillomavirus-Related Squamous Cell Carcinoma

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

No longer available

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Growth Disorders | Proteus Syndrome | PIK3CA-Related Overgrowth Spectrum (PROS)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

China
National Human Genome Research Institute (NHGRI)
Children's National Research Institute; Uniformed Services University of the...

Recruiting

Study of Proteus Syndrome and Related Congenital Disorders

Proteus Syndrome | PIK3CA Related Overgrowth Spectrum

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

United States, Australia, Brazil, Italy, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...
Worldwide Clinical Trials

Terminated

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

United States, Australia, Italy, Spain
AstraZeneca

Completed

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Advanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation

United States, United Kingdom
Korean Cancer Study Group

Active, not recruiting

Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients (ALCAP)

Metastatic Colorectal Cancer | PIK3CA Gene Mutation

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Estrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA Gene

United States, Netherlands, Spain, Germany, United Kingdom
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Novartis Pharmaceuticals

Recruiting

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Spain, Italy, Austria
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
Institut National de la Santé Et de la Recherche...

Recruiting

National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) (COSY)

Vascular Malformations | PIK3CA-related Overgrowth Spectrum | Megalencephaly | Lymphatic Malformation | CLOVES Syndrome | Venous Malformation | Klippel Trenaunay Syndrome | MCAP | Macrodactyly

France
Dr Cipto Mangunkusumo General Hospital

Completed

Patogenic Mutation in 5 Genes

Colorectal Cancer | APC Gene Mutation | TP53 Gene Mutation | PIK3CA Gene Mutation | KRAS Mutation-Related Tumors | MLH1 Gene Mutation

Indonesia
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Tempest Therapeutics

Active, not recruiting

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Colorectal Cancer | Solid Tumor | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Solid Tumors With PIK3Ca Mutation

United States
Simons Searchlight
Boston Children's Hospital; Geisinger Clinic; Simons Foundation

Recruiting

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

SMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditions

United States

Clinical Trials on PPP3CA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations